Loading...
Chronic myelogenous leukemia initiating cells require Polycomb group protein EZH2
Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myelogenous leukemia (CML) management. Disease eradication, however, is hampered by innate resistance of leukemia initiating cells (LICs) to TKI-induced killing, which also provides the basis for subsequent emergence of TKI-resistant muta...
Na minha lista:
| Udgivet i: | Cancer Discov |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5096974/ https://ncbi.nlm.nih.gov/pubmed/27630126 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1439 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|